Dataset Information

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

ABSTRACT: Small cell lung cancer (SCLC) patient-derived xenografts (PDX) can be generated from biopsies or circulating tumor cells (CTC), though scarcity of tissue and low efficiency of tumor growth have previously limited these approaches. Applying an established clinical-translational pipeline for tissue collection and an automated microfluidic platform for CTC enrichment, we generated 17 biopsy-derived PDXs and 17 CTC-derived PDXs in a 2-year timeframe, at 89% and 38% efficiency, respectively. Whole-exome sequencing showed that somatic alterations are stably maintained between patient tumors and PDXs. Early-passage PDXs maintain the genomic and transcriptional profiles of the founder PDX. In vivo treatment with etoposide and platinum (EP) in 30 PDX models demonstrated greater sensitivity in PDXs from EP-naïve patients, and resistance to EP corresponded to increased expression of a MYC gene signature. Finally, serial CTC-derived PDXs generated from an individual patient at multiple time points accurately recapitulated the evolving drug sensitivities of that patient's disease. Collectively, this work highlights the translational potential of this strategy.Significance: Effective translational research utilizing SCLC PDX models requires both efficient generation of models from patients and fidelity of those models in representing patient tumor characteristics. We present approaches for efficient generation of PDXs from both biopsies and CTCs, and demonstrate that these models capture the mutational landscape and functional features of the donor tumors. Cancer Discov; 8(5); 600-15. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 517.

SUBMITTER: Drapkin BJ

PROVIDER: S-EPMC6369413 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Drapkin Benjamin J BJ George Julie J Christensen Camilla L CL Mino-Kenudson Mari M Dries Ruben R Sundaresan Tilak T Phat Sarah S Myers David T DT Zhong Jun J Igo Peter P Hazar-Rethinam Mehlika H MH Licausi Joseph A JA Gomez-Caraballo Maria M Kem Marina M Jani Kandarp N KN Azimi Roxana R Abedpour Nima N Menon Roopika R Lakis Sotirios S Heist Rebecca S RS Büttner Reinhard R Haas Stefan S Sequist Lecia V LV Shaw Alice T AT Wong Kwok-Kin KK Hata Aaron N AN Toner Mehmet M Maheswaran Shyamala S Haber Daniel A DA Peifer Martin M Dyson Nicholas N Thomas Roman K RK Farago Anna F AF

Cancer discovery 20180226 5

Small cell lung cancer (SCLC) patient-derived xenografts (PDX) can be generated from biopsies or circulating tumor cells (CTC), though scarcity of tissue and low efficiency of tumor growth have previously limited these approaches. Applying an established clinical-translational pipeline for tissue collection and an automated microfluidic platform for CTC enrichment, we generated 17 biopsy-derived PDXs and 17 CTC-derived PDXs in a 2-year timeframe, at 89% and 38% efficiency, respectively. Whole-ex ...[more]

PMID: 29483136

Similar Datasets

Project description:BACKGROUND:Patient-derived xenograft (PDX) models increasingly are used in translational research. However, the engraftment rates of patient tumor samples in immunodeficient mice to PDX models vary greatly. METHODS:Tumor tissue samples from 308 patients with non-small cell lung cancer were implanted in immunodeficient mice. The patients were followed for 1.5 to approximately 6 years. The authors performed histological analysis of PDXs and some residual tumor tissues in mice with failed PDX growth at 1 year after implantation. Quantitative polymerase chain reaction and enzyme-linked immunoadsorbent assay were performed to measure the levels of Epstein-Barr virus genes and human immunoglobulin G in PDX samples. Patient characteristics were compared for PDX growth and overall survival as outcomes using Cox regression analyses. Disease staging was based on the 7th TNM staging system. RESULTS:The overall engraftment rate for PDXs from patients with non-small cell lung cancer was 34%. Squamous cell carcinomas had a higher engraftment rate (53%) compared with adenocarcinomas. Tumor samples from patients with stage II and stage III disease and from larger tumors were found to have relatively high engraftment rates. Patients whose tumors successfully engrafted had worse overall survival, particularly those individuals with adenocarcinoma, stage III or stage IV disease, and moderately differentiated tumors. Lymphoma formation was one of the factors associated with engraftment failure. Human CD8-positive and CD20-positive cells were detected in residual samples of tumor tissue that failed to generate a PDX at 1 year after implantation. Human immunoglobulin G was detected in the plasma of mice that did not have PDX growth at 14 months after implantation. CONCLUSIONS:The results of the current study indicate that the characteristics of cancer cells and the tumor immune microenvironment in primary tumors both can affect engraftment of a primary tumor sample.

Dataset Information

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Publications

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets